EnteroBiotix, a biopharmaceutical company developing novel highly-diverse microbial therapeutics that enhance the gut microbiome, today announced the Board appointment of David Lawrence as an independent Non-Executive Director.

EnteroBiotix is pleased to announce that the Company has received full registration of their trademark “Number 2”. The Number 2 brand forms a core part of the Company’s strategy to control the supply chain for its Broad Spectrum Microbiota™ therapeutics.

Watch an interview with our Founder and CEO Dr. James McIlroy, where he shares our vision for mastering the microbiome to transform lives of patients.

This Boston based event is the most comprehensive forum for microbiome drug developers. Email us to arrange meeting up at the event.

BioTrinity is an established, must-attend London conference, that catalyses growth and supports in-person re-engagement across the life sciences industry. Email us to arrange meeting up at the event.

Our Founder & CEO Dr James McIlroy was recently featured on The Pharma Letter podcast with Simon Wentworth discussing mastering the microbiome

Originally published in Fierce Biotech. EnteroBiotix, a Scottish biopharma focused on making gut microbiome therapies, said construction of its new manufacturing, lab and office facility has been completed.

Glasgow, Scotland – 27 October 2021 – EnteroBiotix, a biopharmaceutical company developing novel highly-diverse microbial therapeutics that enhance the gut microbiome, today announced the mechanical completion of a new purpose built world-class facility at Strathclyde Business Park, Glasgow

Originally published in Fierce Biotech. EnteroBiotix has rounded up $21.5 million in a series A financing to advance a pipeline of drugs targeting the microbiome, which is believed to play a role in overall health.

Originally published in Endpoint News. Scottish biopharma Enterobiotix today announced the closing of its $21.5 million Series A financing. The proceeds will be used to further advance the company’s microbiome drug pipeline and support its product development and manufacturing capabilities.

Glasgow, Scotland – 7th September 2021 – EnteroBiotix, a biopharmaceutical company developing novel high-diversity microbial therapeutics that enhance the gut microbiome and target multiple indications, today announced the final closing of its oversubscribed USD $21.5 million (UK £15.5m) Series A financing. The proceeds will be used to further advance the company’s microbiome drug pipeline and underpin its product development and manufacturing capabilities.